Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX7353 for Acute HAE Attacks (ZENITH-1)
NCT03240133Phase 2Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Jul 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of berotralstat in hereditary angioedema (HAE), sponsored by BioCryst Pharmaceuticals, Inc.. Started Jul 2017; status: completed.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT03240133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03240133.